Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bolivia signs contract with India's Serum Institute for 5 million AstraZeneca vaccine doses

01/13/2021 | 12:01pm EST
FILE PHOTO: Vials of AstraZeneca's COVISHIELD, coronavirus disease (COVID-19) vaccine, are seen before they are packaged inside a lab at Serum Institute of India, Pune

LA PAZ (Reuters) - The Bolivian government said on Wednesday it had signed a contract with India's Serum Institute for the supply of 5 million doses of AstraZeneca's COVID-19 vaccine.

President Luis Arce said that combined with a recent deal to buy 5.2 million Sputnik V vaccine doses from Russia, Bolivia now expected to be able to inoculate all of its vaccinable population.

Both vaccines require two doses to be given, meaning they would be used to inoculate a total of 5.1 million people from Bolivia's 11.51 million-strong population.

Bolivia has also signed an agreement through the global COVAX initiative, which is backed by the World Health Organization and seeks to ensure equitable distribution of vaccines, to receive a further 3.6 million doses of a range of vaccines.

Bolivia, which has endured periods of political and social disruption since contested elections in 2019 saw longtime president Evo Morales leave office, has struggled to secure bilateral vaccine supply deals.

Arce said the first million AstraZeneca doses would arrive in Bolivia in April. The first 6,000 Sputnik doses are expected to arrive at the end of January.

Bolivia also took delivery of 650,000 of a promised 1.6 million consignment of COVID-19 tests from South Korea this week. The nasal antigen tests will allow Bolivia to roll out widespread testing for the disease for the first time since the pandemic broke out, potentially resulting in a spike in reported infection numbers.

On Tuesday, the health ministry reported 1,473 new cases, 176,761 cases in total and 9,454 dead.

(Reporting By Danny Ramos; Writing by Christian Plumb and Aislinn Laing; Editing by Daniel Flynn, Kirsten Donovan)

By Danny Ramos

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.66% 7777 Delayed Quote.6.19%
DECIPHERA PHARMACEUTICALS, INC. -1.02% 46.76 Delayed Quote.-18.07%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) 1.61% 75.12 Delayed Quote.0.19%
All news about ASTRAZENECA PLC
03:45aASTRAZENECA : UK doctors call for shorter gap between Pfizer vaccine doses
01/22Health Care Down Amid Vaccine-Rollout Concerns -- Health Care Roundup
01/22THE LATEST : Online vaccine appointments filling up in Kansas
01/22ALEXION INVESTOR ALERT BY THE FORMER : Kahn Swick & Foti, LLC Investigates Adequ..
01/22Pfizer to supply 40M COVID-19 shots for poor countries
01/22ASTRAZENECA : to supply 31 mln COVID-19 shots to EU in first quarter, a 60% cut ..
01/22AstraZeneca Warns of Covid-19 Vaccine Shortfall in Europe -- Update
01/22AstraZeneca Warns of Covid-19 Vaccine Shortfall in Europe
01/22ASTRAZENECA : Warns of Fewer COVID-19 Vaccines in Europe
01/22ASTRAZENECA : to cut EU's COVID-19 vaccine deliveries by 60% in Q1 -EU source
More news
Financials (USD)
Sales 2020 26 404 M - -
Net income 2020 2 955 M - -
Net Debt 2020 13 238 M - -
P/E ratio 2020 42,5x
Yield 2020 2,65%
Capitalization 140 B 139 B -
EV / Sales 2020 5,79x
EV / Sales 2021 4,98x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 126,44 $
Last Close Price 106,39 $
Spread / Highest target 46,7%
Spread / Average Target 18,8%
Spread / Lowest Target -15,2%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159